Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.68 USD | -2.65% | -13.00% | -60.47% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 302M |
---|---|---|---|---|---|
Net income 2024 * | -46M | Net income 2025 * | -72M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.46
x | P/E ratio 2025 * |
-4.23
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.86% |
Latest transcript on Anavex Life Sciences Corp.
1 day | -2.65% | ||
1 week | -13.00% | ||
Current month | -27.70% | ||
1 month | -21.03% | ||
3 months | -44.24% | ||
6 months | -29.23% | ||
Current year | -60.47% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Sandra Boenisch
DFI | Director of Finance/CFO | 43 | 15-09-30 |
Edward Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Tom Skarpelos
FOU | Founder | 57 | 04-01-22 |
Jiong Ma
CHM | Chairman | 60 | 21-05-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.07% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 3.68 | -2.65% | 1,358,524 |
24-04-19 | 3.78 | -0.53% | 2,084,019 |
24-04-18 | 3.8 | -6.63% | 1,659,800 |
24-04-17 | 4.07 | -1.21% | 1,337,487 |
24-04-16 | 4.12 | -2.60% | 1,252,081 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.47% | 302M | |
+2.49% | 96.73B | |
-0.20% | 21.31B | |
-16.61% | 21.21B | |
-5.24% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B |
- Stock Market
- Equities
- AVXL Stock